A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities
Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced card...
Gespeichert in:
| Veröffentlicht in: | Oxidative medicine and cellular longevity 2021, Vol.2021 (1), p.2951697 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2951697 |
| container_title | Oxidative medicine and cellular longevity |
| container_volume | 2021 |
| creator | Hu, Li-Feng Lan, Huan-Rong Li, Xue-Min Jin, Ke-Tao |
| description | Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory. |
| doi_str_mv | 10.1155/2021/2951697 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2569272148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-f19b31f27ebc1ba5b471841599e5bab405c271f30465a47e017274bf1a333913</originalsourceid><addsrcrecordid>eNp9kV1r2zAUhsXYWNtsd7segl0uXvVlO9rFIKTtVihsdL0XkiwtKrblSXLa_Lf-uMpNFtabgkDn4-E9r3QA-IDRF4zL8pQggk8JL3HF61fgGHNGCsQ5e32IEToCJzHeIlRRwvBbcEQZqzGr6DF4WMLf25hMJ5PT8NpsnLmD3sK0NvCXT6ZPTrZwtTadH0LOdXIbA8-tzVGcwGsTNybIFHwLfQ_P_L0Po3La9cVl34zaNHAlQ-N88ve5mrZf4YXXY5zgacgyT8idRvZp_pTIwQ_JZzdzKPvmqZSVbCu77NGHLVxOHlxyJr4Db6xso3m_v2fg5uL8ZvWjuPr5_XK1vCo0Y4tUWMwVxZbURmmsZKny4xcMl5ybUknFUKlJjS1FrColqw3CNamZslhSSjmmM_BtJzuMqjONzp8SZCuG4DoZtsJLJ553ercWf_xGLLI0zWcGPu0Fgv87mpjErR9Dny0LUlac1ASzRabmO0oHH2Mw9jABIzGtWkyrFvtVZ_zj_64O8L_dZuDzDli7vpF37mW5R-46tWU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2569272148</pqid></control><display><type>article</type><title>A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Hu, Li-Feng ; Lan, Huan-Rong ; Li, Xue-Min ; Jin, Ke-Tao</creator><contributor>Rupasinghe, H. P. Vasantha ; H P Vasantha Rupasinghe</contributor><creatorcontrib>Hu, Li-Feng ; Lan, Huan-Rong ; Li, Xue-Min ; Jin, Ke-Tao ; Rupasinghe, H. P. Vasantha ; H P Vasantha Rupasinghe</creatorcontrib><description>Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory.</description><identifier>ISSN: 1942-0900</identifier><identifier>EISSN: 1942-0994</identifier><identifier>DOI: 10.1155/2021/2951697</identifier><identifier>PMID: 34471463</identifier><language>eng</language><publisher>United States: Hindawi</publisher><subject>Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Antioxidants ; Antioxidants - pharmacology ; Antioxidants - therapeutic use ; Apoptosis - drug effects ; Bias ; Breast cancer ; Cardiotoxicity ; Cardiotoxicity - drug therapy ; Cardiotoxicity - etiology ; Chemotherapy ; Confidence intervals ; Doxorubicin - adverse effects ; Funding ; Humans ; Information sources ; Lung cancer ; Lymphoma ; Meta-analysis ; Radiation therapy ; Registration ; Resveratrol - pharmacology ; Resveratrol - therapeutic use ; Review ; Systematic review ; Testicular cancer</subject><ispartof>Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.2951697</ispartof><rights>Copyright © 2021 Li-Feng Hu et al.</rights><rights>Copyright © 2021 Li-Feng Hu et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Li-Feng Hu et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-f19b31f27ebc1ba5b471841599e5bab405c271f30465a47e017274bf1a333913</citedby><cites>FETCH-LOGICAL-c448t-f19b31f27ebc1ba5b471841599e5bab405c271f30465a47e017274bf1a333913</cites><orcidid>0000-0002-8700-755X ; 0000-0003-4026-7474 ; 0000-0003-2624-1980 ; 0000-0001-9810-5342</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405305/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405305/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4009,27902,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34471463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Rupasinghe, H. P. Vasantha</contributor><contributor>H P Vasantha Rupasinghe</contributor><creatorcontrib>Hu, Li-Feng</creatorcontrib><creatorcontrib>Lan, Huan-Rong</creatorcontrib><creatorcontrib>Li, Xue-Min</creatorcontrib><creatorcontrib>Jin, Ke-Tao</creatorcontrib><title>A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities</title><title>Oxidative medicine and cellular longevity</title><addtitle>Oxid Med Cell Longev</addtitle><description>Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory.</description><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antioxidants</subject><subject>Antioxidants - pharmacology</subject><subject>Antioxidants - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Bias</subject><subject>Breast cancer</subject><subject>Cardiotoxicity</subject><subject>Cardiotoxicity - drug therapy</subject><subject>Cardiotoxicity - etiology</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Doxorubicin - adverse effects</subject><subject>Funding</subject><subject>Humans</subject><subject>Information sources</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Meta-analysis</subject><subject>Radiation therapy</subject><subject>Registration</subject><subject>Resveratrol - pharmacology</subject><subject>Resveratrol - therapeutic use</subject><subject>Review</subject><subject>Systematic review</subject><subject>Testicular cancer</subject><issn>1942-0900</issn><issn>1942-0994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV1r2zAUhsXYWNtsd7segl0uXvVlO9rFIKTtVihsdL0XkiwtKrblSXLa_Lf-uMpNFtabgkDn4-E9r3QA-IDRF4zL8pQggk8JL3HF61fgGHNGCsQ5e32IEToCJzHeIlRRwvBbcEQZqzGr6DF4WMLf25hMJ5PT8NpsnLmD3sK0NvCXT6ZPTrZwtTadH0LOdXIbA8-tzVGcwGsTNybIFHwLfQ_P_L0Po3La9cVl34zaNHAlQ-N88ve5mrZf4YXXY5zgacgyT8idRvZp_pTIwQ_JZzdzKPvmqZSVbCu77NGHLVxOHlxyJr4Db6xso3m_v2fg5uL8ZvWjuPr5_XK1vCo0Y4tUWMwVxZbURmmsZKny4xcMl5ybUknFUKlJjS1FrColqw3CNamZslhSSjmmM_BtJzuMqjONzp8SZCuG4DoZtsJLJ553ercWf_xGLLI0zWcGPu0Fgv87mpjErR9Dny0LUlac1ASzRabmO0oHH2Mw9jABIzGtWkyrFvtVZ_zj_64O8L_dZuDzDli7vpF37mW5R-46tWU</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Hu, Li-Feng</creator><creator>Lan, Huan-Rong</creator><creator>Li, Xue-Min</creator><creator>Jin, Ke-Tao</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8700-755X</orcidid><orcidid>https://orcid.org/0000-0003-4026-7474</orcidid><orcidid>https://orcid.org/0000-0003-2624-1980</orcidid><orcidid>https://orcid.org/0000-0001-9810-5342</orcidid></search><sort><creationdate>2021</creationdate><title>A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities</title><author>Hu, Li-Feng ; Lan, Huan-Rong ; Li, Xue-Min ; Jin, Ke-Tao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-f19b31f27ebc1ba5b471841599e5bab405c271f30465a47e017274bf1a333913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antioxidants</topic><topic>Antioxidants - pharmacology</topic><topic>Antioxidants - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Bias</topic><topic>Breast cancer</topic><topic>Cardiotoxicity</topic><topic>Cardiotoxicity - drug therapy</topic><topic>Cardiotoxicity - etiology</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Doxorubicin - adverse effects</topic><topic>Funding</topic><topic>Humans</topic><topic>Information sources</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Meta-analysis</topic><topic>Radiation therapy</topic><topic>Registration</topic><topic>Resveratrol - pharmacology</topic><topic>Resveratrol - therapeutic use</topic><topic>Review</topic><topic>Systematic review</topic><topic>Testicular cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Li-Feng</creatorcontrib><creatorcontrib>Lan, Huan-Rong</creatorcontrib><creatorcontrib>Li, Xue-Min</creatorcontrib><creatorcontrib>Jin, Ke-Tao</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oxidative medicine and cellular longevity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Li-Feng</au><au>Lan, Huan-Rong</au><au>Li, Xue-Min</au><au>Jin, Ke-Tao</au><au>Rupasinghe, H. P. Vasantha</au><au>H P Vasantha Rupasinghe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities</atitle><jtitle>Oxidative medicine and cellular longevity</jtitle><addtitle>Oxid Med Cell Longev</addtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><issue>1</issue><spage>2951697</spage><pages>2951697-</pages><issn>1942-0900</issn><eissn>1942-0994</eissn><abstract>Purpose. Although doxorubicin chemotherapeutic drug is commonly used to treat various solid and hematological tumors, its clinical use is restricted because of its adverse effects on the normal cells/tissues, especially cardiotoxicity. The use of resveratrol may mitigate the doxorubicin-induced cardiotoxic effects. For this aim, we systematically reviewed the potential chemoprotective effects of resveratrol against the doxorubicin-induced cardiotoxicity. Methods. In the current study, a systematic search was performed based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for the identification of all relevant studies on “the role of resveratrol on doxorubicin-induced cardiotoxicity” in the electronic databases of Web of Science, PubMed, and Scopus up to March 2021 using search terms in their titles and abstracts. Two hundred and eighteen articles were screened in accordance with a predefined set of inclusion and exclusion criteria. Finally, 33 eligible articles were included in this systematic review. Results. The in vitro and in vivo findings demonstrated a decreased cell survival, increased mortality, decreased heart weight, and increased ascites in the doxorubicin-treated groups compared to the control groups. The combined treatment of resveratrol and doxorubicin showed an opposite pattern than the doxorubicin-treated groups alone. Furthermore, this chemotherapeutic agent induced the biochemical and histopathological changes on the cardiac cells/tissue; however, the results (for most of the cases) revealed that these alterations induced by doxorubicin were reversed near to normal levels (control groups) by resveratrol coadministration. Conclusion. The results of this systematic review stated that coadministration of resveratrol alleviates the doxorubicin-induced cardiotoxicity. Resveratrol exerts these chemoprotective effects through several main mechanisms of antioxidant, antiapoptosis, and anti-inflammatory.</abstract><cop>United States</cop><pub>Hindawi</pub><pmid>34471463</pmid><doi>10.1155/2021/2951697</doi><orcidid>https://orcid.org/0000-0002-8700-755X</orcidid><orcidid>https://orcid.org/0000-0003-4026-7474</orcidid><orcidid>https://orcid.org/0000-0003-2624-1980</orcidid><orcidid>https://orcid.org/0000-0001-9810-5342</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1942-0900 |
| ispartof | Oxidative medicine and cellular longevity, 2021, Vol.2021 (1), p.2951697 |
| issn | 1942-0900 1942-0994 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405305 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Antioxidants Antioxidants - pharmacology Antioxidants - therapeutic use Apoptosis - drug effects Bias Breast cancer Cardiotoxicity Cardiotoxicity - drug therapy Cardiotoxicity - etiology Chemotherapy Confidence intervals Doxorubicin - adverse effects Funding Humans Information sources Lung cancer Lymphoma Meta-analysis Radiation therapy Registration Resveratrol - pharmacology Resveratrol - therapeutic use Review Systematic review Testicular cancer |
| title | A Systematic Review of the Potential Chemoprotective Effects of Resveratrol on Doxorubicin-Induced Cardiotoxicity: Focus on the Antioxidant, Antiapoptotic, and Anti-Inflammatory Activities |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T04%3A02%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Systematic%20Review%20of%20the%20Potential%20Chemoprotective%20Effects%20of%20Resveratrol%20on%20Doxorubicin-Induced%20Cardiotoxicity:%20Focus%20on%20the%20Antioxidant,%20Antiapoptotic,%20and%20Anti-Inflammatory%20Activities&rft.jtitle=Oxidative%20medicine%20and%20cellular%20longevity&rft.au=Hu,%20Li-Feng&rft.date=2021&rft.volume=2021&rft.issue=1&rft.spage=2951697&rft.pages=2951697-&rft.issn=1942-0900&rft.eissn=1942-0994&rft_id=info:doi/10.1155/2021/2951697&rft_dat=%3Cproquest_pubme%3E2569272148%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2569272148&rft_id=info:pmid/34471463&rfr_iscdi=true |